Clinical Trials
5 trialsNCT03486873 2026-06-05
MK-3475-587
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07005102 2026-06-05
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT04567420 2026-06-03
DARE
Criterium, Inc.
Phase 2 Recruiting
NCT07206056 2026-06-03
TulmiSTAR-01
Novartis
Phase 1/2 Recruiting
NCT07023289 2026-06-02
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
AbbVie
Phase 2 Recruiting